Evidence map›Paper›PMID 37522388›Full record

ArticleCancer science2023

Identification of compounds that preferentially suppress the growth of T-cell acute lymphoblastic leukemia-derived cells.

Kazuya Miyashita, Takuya Yagi, Noritaka Kagaya, Azusa Takechi, Chihiro Nakata, Risa Kanda, Hideko Nuriya, Kosuke Tanegashima, Shota Hoyano, Fumiya Seki and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Kazuya MiyashitaStem Cell Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Japan.
Takuya YagiStem Cell Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Japan.
Noritaka KagayaNational Institute of Advanced Industrial Science and Technology, Koto-ku, Japan.
Azusa TakechiStem Cell Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Japan.
Chihiro NakataStem Cell Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Japan.
Risa KandaStem Cell Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Japan.
Hideko NuriyaCore Technology and Research Center, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Japan.
Kosuke TanegashimaStem Cell Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Japan.
Shota HoyanoStem Cell Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Japan.
Fumiya SekiStem Cell Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Japan.
Chihiro YoshidaDepartment of Engineering Science, Graduate School of Informatics and Engineering, The University of Electro-Communications, Chofu, Japan.
Yoshifumi HachiroDepartment of Engineering Science, Graduate School of Informatics and Engineering, The University of Electro-Communications, Chofu, Japan.
Tomoya HigashiDepartment of Engineering Science, Graduate School of Informatics and Engineering, The University of Electro-Communications, Chofu, Japan.
Nobuo KitadaDepartment of Engineering Science, Graduate School of Informatics and Engineering, The University of Electro-Communications, Chofu, Japan.
Takashi ToyaHematology Division, Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital, Bunkyo-ku, Japan.ORCID https://orcid.org/0000-0002-7436-972X
Takeshi KobayashiHematology Division, Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital, Bunkyo-ku, Japan.
Yuho NajimaHematology Division, Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital, Bunkyo-ku, Japan.ORCID https://orcid.org/0000-0001-8910-0021
Susumu GoyamaDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Japan.ORCID https://orcid.org/0000-0002-9339-1826
Shojiro A MakiDepartment of Engineering Science, Graduate School of Informatics and Engineering, The University of Electro-Communications, Chofu, Japan.
Toshio KitamuraDivision of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Japan.
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital, Bunkyo-ku, Japan.
Kazuo Shin-YaNational Institute of Advanced Industrial Science and Technology, Koto-ku, Japan.
Takahiko HaraStem Cell Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Japan.ORCID https://orcid.org/0000-0002-6565-0720

Funding

AMED JP18lm0203004
6 · The paper itself

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is one of the most frequently occurring cancers in children and is associated with a poor prognosis. Here, we performed large-scale screening of natural compound libraries to identify potential drugs against T-ALL. We identified three low-molecular-weight compounds (auxarconjugatin-B, rumbrin, and lavendamycin) that inhibited the proliferation of the T-ALL cell line CCRF-CEM, but not that of the B lymphoma cell line Raji in a low concentration range. Among them, auxarconjugatin-B and rumbrin commonly contained a polyenyl 3-chloropyrrol in their chemical structure, therefore we chose auxarconjugatin-B for further analyses. Auxarconjugatin-B suppressed the in vitro growth of five human T-ALL cell lines and two T-ALL patient-derived cells, but not that of adult T-cell leukemia patient-derived cells. Cultured normal T cells were several-fold resistant to auxarconjugatin-B. Auxarconjugatin-B and its synthetic analogue Ra#37 depolarized the mitochondrial membrane potential of CCRF-CEM cells within 3 h of treatment. These compounds are promising seeds for developing novel anti-T-ALL drugs.

Indexed as

Antineoplastic AgentsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMembrane Potential, MitochondrialT-LymphocytesAntineoplastic Agentsanticancer compoundsdepolarizationleukemiamitochondriaT-ALL

Identifiers

PMID37522388
PMCPMC10551604

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.